Close Menu

NEW YORK (360Dx) – BioReference Laboratories' GenPath Oncology Diagnostics division will participate in the National Cancer Institute's Molecular Analysis for Therapy Choice (NCI-MATCH) trial.

BioReference Labs signed a collaboration agreement with the National Cancer Institute and ECOG-ACRIN Cancer Research Group, which is coordinating the trial, BioReference parent company Opko Health announced today.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
10
Sponsored by
MeMed

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.